Q2 EPS Estimate for Eton Pharmaceuticals Raised by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Research analysts at HC Wainwright boosted their Q2 2025 EPS estimates for Eton Pharmaceuticals in a note issued to investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.17 for the quarter, up from their previous forecast of $0.08. HC Wainwright currently has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.34 EPS, FY2025 earnings at $0.81 EPS, FY2026 earnings at $2.01 EPS, FY2027 earnings at $2.63 EPS, FY2028 earnings at $3.82 EPS and FY2029 earnings at $4.89 EPS.

A number of other analysts also recently issued reports on the stock. Craig Hallum raised their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. B. Riley initiated coverage on Eton Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $21.00 price target on the stock.

Eton Pharmaceuticals Trading Up 2.6 %

NASDAQ:ETON opened at $16.67 on Monday. The firm has a market cap of $434.25 million, a P/E ratio of -75.77 and a beta of 1.38. The stock has a 50 day moving average of $12.84 and a two-hundred day moving average of $8.28. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $17.00.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eton Pharmaceuticals in the third quarter worth $54,000. Jane Street Group LLC acquired a new stake in Eton Pharmaceuticals during the third quarter worth approximately $90,000. Baader Bank Aktiengesellschaft purchased a new position in shares of Eton Pharmaceuticals during the 4th quarter worth $373,000. Connor Clark & Lunn Investment Management Ltd. increased its stake in Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after purchasing an additional 30,167 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares during the period. 27.86% of the stock is owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.